Tate Thigpen

Summary

Country: USA

Publications

  1. doi request reprint First-line therapy in ovarian cancer trials
    Tate Thigpen
    GOG, Germany
    Int J Gynecol Cancer 21:756-62. 2011
  2. doi request reprint Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival
    J Tate Thigpen
    Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson, MS, USA Electronic address
    Gynecol Oncol 136:121-9. 2015
  3. doi request reprint A rational approach to the management of recurrent or persistent ovarian carcinoma
    Tate Thigpen
    Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi, USA
    Clin Obstet Gynecol 55:114-30. 2012
  4. ncbi request reprint The role of gemcitabine in first-line treatment of advanced ovarian carcinoma
    Tate Thigpen
    Division of Oncology, University of Mississippi School of Medicine, Jackson, MS 39216, USA
    Semin Oncol 33:S26-32. 2006
  5. ncbi request reprint Role of pegylated liposomal doxorubicin in ovarian cancer
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
    Gynecol Oncol 96:10-8. 2005
  6. ncbi request reprint First-line therapy for ovarian carcinoma: what's next?
    Tate Thigpen
    Department of Medicine, Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi, USA
    Cancer Invest 22:21-8. 2004
  7. ncbi request reprint The role of gemcitabine-based doublets in the management of ovarian carcinoma
    Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA
    Semin Oncol 29:11-6. 2002
  8. ncbi request reprint The role of chemotherapy in the management of carcinoma of the cervix
    Tate Thigpen
    Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA
    Cancer J 9:425-32. 2003
  9. ncbi request reprint Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson, USA
    J Clin Oncol 22:3902-8. 2004
  10. ncbi request reprint Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson, MS 39216 4505, USA
    Gynecol Oncol 90:581-6. 2003

Detail Information

Publications19

  1. doi request reprint First-line therapy in ovarian cancer trials
    Tate Thigpen
    GOG, Germany
    Int J Gynecol Cancer 21:756-62. 2011
    ..who need specific treatment options/trials? A3: Is the 2004 GCIG-recommended standard comparator arm still valid? A4: What is the role of modifying dose, schedule, and delivery of chemotherapy? A5: What role does surgery play today?..
  2. doi request reprint Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival
    J Tate Thigpen
    Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson, MS, USA Electronic address
    Gynecol Oncol 136:121-9. 2015
    ....
  3. doi request reprint A rational approach to the management of recurrent or persistent ovarian carcinoma
    Tate Thigpen
    Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi, USA
    Clin Obstet Gynecol 55:114-30. 2012
    ....
  4. ncbi request reprint The role of gemcitabine in first-line treatment of advanced ovarian carcinoma
    Tate Thigpen
    Division of Oncology, University of Mississippi School of Medicine, Jackson, MS 39216, USA
    Semin Oncol 33:S26-32. 2006
    ..The role of gemcitabine in first-line advanced ovarian cancer will become much clearer once the results from the various phase III trials are published...
  5. ncbi request reprint Role of pegylated liposomal doxorubicin in ovarian cancer
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
    Gynecol Oncol 96:10-8. 2005
    ..The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin...
  6. ncbi request reprint First-line therapy for ovarian carcinoma: what's next?
    Tate Thigpen
    Department of Medicine, Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi, USA
    Cancer Invest 22:21-8. 2004
    ..An overview of current management and its basis will be followed by a discussion of the rationale for both current and potential future trials...
  7. ncbi request reprint The role of gemcitabine-based doublets in the management of ovarian carcinoma
    Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA
    Semin Oncol 29:11-6. 2002
    ..A gemcitabine/carboplatin doublet for four cycles followed by four cycles of paclitaxel/carboplatin is currently under evaluation in a randomized phase III trial (Gynecologic Oncology Group [GOG] protocol 0182)...
  8. ncbi request reprint The role of chemotherapy in the management of carcinoma of the cervix
    Tate Thigpen
    Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA
    Cancer J 9:425-32. 2003
    ..This article examines the role of chemotherapy, particularly in those patients with disseminated disease and those with locally advanced disease in the pelvis...
  9. ncbi request reprint Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson, USA
    J Clin Oncol 22:3902-8. 2004
    ..This trial of stage III, IV, or recurrent disease evaluated whether combining these agents increases response rate (RR) and prolongs progression-free survival (PFS) and overall survival (OS) over doxorubicin alone...
  10. ncbi request reprint Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson, MS 39216 4505, USA
    Gynecol Oncol 90:581-6. 2003
    ..Those patients who had persistent (stable) or progressive disease while receiving paclitaxel, or a recurrence of disease within 6 months of completing six cycles of paclitaxel therapy, received single-agent cisplatin...
  11. ncbi request reprint Management of women who present with T4 breast cancer
    Galen V Poole
    Department of Surgery, Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA
    Am Surg 70:662-6; discussion 666-7. 2004
    ..Multimodality therapy gives the best results, but early surgery may be required for progression of disease during chemotherapy or because of extensive ulceration at initial presentation...
  12. ncbi request reprint ICON3 and chemotherapy for ovarian cancer
    Robert F Ozols
    Lancet 360:2086-7; author reply 2088. 2002
  13. ncbi request reprint The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study
    D Scott McMeekin
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 106:16-22. 2007
    ..To explore associations between histology and outcome in advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials...
  14. ncbi request reprint The role of maintenance therapy and novel taxanes in ovarian cancer
    Thomas J Herzog
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University, Herbert Irving Cancer Center, 161 Ft Washington Avenue, New York, NY 10032, USA
    Gynecol Oncol 102:218-25. 2006
    ..In addition, the role of novel taxanes, which may offer an improved therapeutic index and reduced toxicity relative to conventional therapies in this setting, is discussed...
  15. ncbi request reprint Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study
    Susan C Modesitt
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia, Box 800712, Charlottesville, VA 22908 0712, USA
    Gynecol Oncol 105:59-65. 2007
    ..To evaluate the association between body mass index (BMI) and outcomes in women with advanced or recurrent endometrial cancer treated with doxorubicin/cisplatin...
  16. ncbi request reprint Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study
    G Larry Maxwell
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and the U S Military Cancer Institute, Walter Reed Army Medical Center, Washington, DC, USA
    Cancer 107:2197-205. 2006
    ..Previous studies have reported shorter survival of black women compared with white women who had advanced/recurrent endometrial cancer. It has been suggested that this may reflect racially based differences in treatment...
  17. ncbi request reprint Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study
    Marcus E Randall
    Leo W Jenkins Cancer Center, Brody School of Medicine at East Carolina University, Greenville, NC, USA
    J Clin Oncol 24:36-44. 2006
    ..To compare whole-abdominal irradiation (WAI) and doxorubicin-cisplatin (AP) chemotherapy in women with stage III or IV endometrial carcinoma having a maximum of 2 cm of postoperative residual disease...
  18. ncbi request reprint Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop
    Robert C Bast
    M D Anderson Cancer Center, Houston, TX, USA
    Gynecol Oncol 107:173-6. 2007
    ....
  19. ncbi request reprint Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Case Western Reserve University and Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 25:2804-10. 2007
    ....